User:Mr. Ibrahem/Dolutegravir

Dolutegravir (DTG), sold under the brand name Tivicay, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.

Common side effects include trouble sleeping, feeling tired, diarrhea, high blood sugar, and headache. Severe side effects may include allergic reactions and liver problems. There is tentative concerns that use during pregnancy can result in harm to the baby. It is unclear if use during breastfeeding is safe. Dolutegravir is an HIV integrase strand transfer inhibitor which blocks the functioning of HIV integrase which is needed for viral replication.

Dolutegravir was approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines. In 2015, the cost of the medication in the United Kingdom was £499 per month. Abacavir/dolutegravir/lamivudine, a combination with abacavir and lamivudine is also available. As of 2019, the WHO recommends DTG as the first- and second-line treatment for all persons with HIV.